FDA Finalizes Adhesion Rules for Generic Skin Patches

FDA has finalized its guidance on how generic drugmakers should test whether a transdermal or topical patch stays stuck to the skin. "Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs" closes out a document that has now gone through an original draft and two revisions since 2016. The notice of availability appeared for public inspection on 31 July 2026 and is scheduled to publish formally in the Federal Register on 3 August, under Docket No. FDA-2016-D-1254.

Why adhesion gets its own guidance

A generic transdermal patch has to match its reference product on more than the drug it delivers. If a patch lifts at the corner, folds over, or falls off before its labeled wear time, the dose a patient actually receives can fall short of what the label promises — a failure mode a tablet's bioequivalence data would never catch. FDA's guidance is CDER's answer to that gap: recommendations for designing and running adhesion studies specifically for Abbreviated New Drug Applications, the pathway generic sponsors use to reference an already-approved brand product rather than running a full clinical program of their own. Depending on a program's goals, the guidance lets applicants run adhesion evaluation as its own study or fold it into a combined study that also measures bioequivalence through pharmacokinetic endpoints — one clinical visit doing double duty instead of two.

Three drafts, eight years, no changes

The guidance's paper trail is its own small case study in how FDA generic-drug guidance actually moves. FDA published the original draft on 1 June 2016. A Revision 1 draft followed 10 October 2018, then a Revision 2 draft on 13 April 2023 with a comment window that closed 12 June 2023. According to FDA's own account of the process, that Revision 2 draft drew no comments at all — and the guidance finalized this week reproduces it without change. Eight years and three published versions later, the operative text a generic sponsor has to work from this week is identical to what FDA proposed in April 2023. That is not typical: most CDER guidances that reach final form incorporate at least some comment-driven edits along the way, even minor ones. Here, silence from industry appears to have been read as agreement, and FDA finalized what it had already put on the table.

What sponsors do with it now

For a program already built around the Revision 2 draft — and, three years after its publication, many likely are — finalization changes nothing about the underlying testing recommendations. What it changes is citability: a final guidance for industry is a formal expression of FDA's current thinking that the agency will hold itself and applicants to during review, in a way a draft, however old, does not. Generic sponsors with transdermal or topical programs in development now have a citable, final reference for adhesion study design instead of a three-year-old draft that could, in principle, still have been revised again before finalization. It is a small, procedural closing of a loop — the kind of guidance news that never makes an advisory committee agenda, but that a regulatory affairs team preparing an ANDA submission checks against line by line, the same way a generics team once needed final word on FDA's retirement of a 1995 topical corticosteroids guidance before finalizing its own bioequivalence protocol.